---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-073284"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2022-06-22T23:59:59+00:00"
generated_at: "2026-06-24T23:50:22.322824+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rockwell Medical CEO Russell Ellison steps down; Mark Strobeck appointed CEO; DaVita gets $7.5M preferred stock

## Summary
- CEO Russell Ellison steps down effective June 30, 2022; severance includes $500K base salary and $350K target bonus over 12 months plus option vesting extension.
- Mark Strobeck appointed President and CEO effective July 1, 2022; base salary $550K, target bonus 60%, initial time-based option grant of 400,000 shares.
- Issued additional 7,500 shares of Series X Convertible Preferred Stock to DaVita on June 16, 2022 for gross proceeds of $7.5 million (second closing under SPA).
- Dr. Strobeck also appointed to the Board as a Class III director with term through 2024 annual meeting.

## SEC filing metadata
- accession: 0001104659-22-073284
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2022-06-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000110465922073284/0001104659-22-073284-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000110465922073284/tm2219051d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-073284
- JSON: https://secwatch.observer/filing/0001104659-22-073284.json
- Plain text: https://secwatch.observer/filing/0001104659-22-073284.txt

## Key facts
- Executive change
  Mark Strobeck was appointed as President and Chief Executive Officer at ROCKWELL MEDICAL, INC..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: the Board appointed Mark Strobeck, Ph.D. as the Company’s President and Chief Executive Officer and as a Class III Director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective July 1, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000110465922073284/0001104659-22-073284-index.htm
- Executive change
  Russell H. Ellison departed as President and Chief Executive Officer at ROCKWELL MEDICAL, INC..
  - Action: stepping down
  - Role: President and Chief Executive Officer
  source text: Russell H. Ellison, M.D., M.Sc., will be stepping down from his role as the President and Chief Executive Officer of the Company, effective as of June 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000110465922073284/0001104659-22-073284-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.